Together, these results demonstrate that TRAIL–CDK9i is more effective than current standard-of-care treatments and it is capable of inducing apoptosis with high efficacy, yet in a cancer-selective manner, in a wide range of human cancer cell lines representing various tumor entities, including PDAC. The gene discussed is TNFSF10; the disease is cancer.